CSCI COSCIENS Biopharma Inc.
Healthcare$2.72+0.00%ClosedMarket Cap: $8.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.46
P/S
1.21
EV/EBITDA
1.40
DCF Value
$-6.41
FCF Yield
-314.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.1%
Operating Margin
-400.4%
Net Margin
-78.9%
ROE
-13.2%
ROA
-9.6%
ROIC
-49.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $2.7M | 35.4% | $-2.4M | $-2.7M | $— | — |
| Q1 null | $1.5M | 29.5% | $-3.6M | $-3.6M | $— | — |
| Q4 null | $3.3M | 61.7% | $-6.4M | $-6.7M | $— | — |
| FY null | $13.8M | 49.3% | $-26.3M | $-15.3M | $— | — |
| Q3 null | $1.9M | 44.7% | $-6.3M | $-5.8M | $— | — |
| Q2 null | $2.3M | 35.0% | $-3.8M | $-1.4M | $— | — |
| Q1 null | $2.1M | 43.9% | $-1.9M | $-1.4M | $— | — |
| Q4 null | $1.4M | 15.8% | $-2.2M | $-1.7M | $— | — |
| FY null | $7.1M | 41.1% | $-4.6M | $-3.5M | $— | — |
| Q3 null | $2.0M | 41.2% | $-1.1M | $-776.0K | $— | — |
| Q2 2023 | $1.4M | 57.3% | $-1.1M | $-860.0K | $-0.47 | — |
| Q1 2023 | $2.6M | 45.9% | $-433.4K | $-284.7K | $-0.15 | — |